Perspective Therapeutics (CATX) Competitors $3.61 -0.29 (-7.44%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$3.66 +0.05 (+1.41%) As of 08/15/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CATX vs. BLFS, MDXG, ESTA, PLSE, INMD, IRMD, TNDM, KMTS, EMBC, and SIBNShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include BioLife Solutions (BLFS), MiMedx Group (MDXG), Establishment Labs (ESTA), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Tandem Diabetes Care (TNDM), Kestra Medical Technologies (KMTS), Embecta (EMBC), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Its Competitors BioLife Solutions MiMedx Group Establishment Labs Pulse Biosciences InMode iRadimed Tandem Diabetes Care Kestra Medical Technologies Embecta SiBone Perspective Therapeutics (NYSE:CATX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings. Is CATX or BLFS more profitable? BioLife Solutions has a net margin of -5.39% compared to Perspective Therapeutics' net margin of -4,096.66%. BioLife Solutions' return on equity of 0.16% beat Perspective Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Perspective Therapeutics-4,096.66% -27.40% -23.16% BioLife Solutions -5.39%0.16%0.14% Do institutionals & insiders have more ownership in CATX or BLFS? 54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer CATX or BLFS? Perspective Therapeutics currently has a consensus target price of $12.56, suggesting a potential upside of 247.80%. BioLife Solutions has a consensus target price of $31.29, suggesting a potential upside of 28.54%. Given Perspective Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Perspective Therapeutics is more favorable than BioLife Solutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18BioLife Solutions 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to CATX or BLFS? In the previous week, Perspective Therapeutics had 2 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Perspective Therapeutics and 8 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.64 beat Perspective Therapeutics' score of 0.55 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perspective Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, CATX or BLFS? BioLife Solutions has higher revenue and earnings than Perspective Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerspective TherapeuticsN/AN/A-$46.51MN/AN/ABioLife Solutions$82.25M14.17-$20.18M-$0.12-202.83 Which has more volatility & risk, CATX or BLFS? Perspective Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. SummaryBioLife Solutions beats Perspective Therapeutics on 8 of the 13 factors compared between the two stocks. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$289.49M$72.71M$5.69B$20.90BDividend YieldN/AN/A3.79%3.58%P/E RatioN/A10.3231.0828.00Price / SalesN/A93.82466.0355.83Price / CashN/A18.4137.4023.77Price / Book1.357.439.095.26Net Income-$46.51M-$25.86M$3.26B$994.11M7 Day Performance-1.90%0.95%7.31%1.80%1 Month Performance-11.52%3.25%5.43%1.74%1 Year Performance-73.12%54.67%30.60%13.36% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics1.6962 of 5 stars$3.61-7.4%$12.56+247.8%-74.1%$289.49MN/A0.0070Analyst RevisionBLFSBioLife Solutions3.2088 of 5 stars$22.37-1.4%$31.29+39.9%-5.5%$1.09B$82.25M-186.40440News CoverageInsider TradeHigh Trading VolumeMDXGMiMedx Group3.2125 of 5 stars$7.04+0.3%$12.00+70.5%+13.4%$1.04B$348.88M33.53870ESTAEstablishment Labs2.0993 of 5 stars$33.63-3.4%$55.80+65.9%-11.4%$1.01B$166.02M-11.031,018News CoverageAnalyst DowngradeHigh Trading VolumePLSEPulse Biosciences3.8477 of 5 stars$14.88+1.2%$22.00+47.8%-15.3%$989.60M$700K0.00140News CoverageEarnings ReportINMDInMode2.8273 of 5 stars$13.80-2.2%$18.04+30.7%-10.2%$891.88M$394.82M5.59480IRMDiRadimed4.4795 of 5 stars$70.00+0.1%$72.00+2.9%+55.9%$889.51M$73.24M43.21110News CoverageTNDMTandem Diabetes Care4.5744 of 5 stars$10.11-10.0%$22.67+124.2%-75.3%$758.80M$940.20M-3.272,650KMTSKestra Medical Technologies1.3641 of 5 stars$14.65+0.9%$27.33+86.6%N/A$745.58M$59.81M0.00300Positive NewsEMBCEmbecta4.7422 of 5 stars$12.73+3.7%$19.00+49.3%-6.1%$717.67M$1.12B8.902,100Positive NewsEarnings ReportAnalyst UpgradeGap UpHigh Trading VolumeSIBNSiBone4.3727 of 5 stars$15.40-1.8%$23.67+53.7%+10.2%$676.45M$167.18M-27.50350 Related Companies and Tools Related Companies BLFS Alternatives MDXG Alternatives ESTA Alternatives PLSE Alternatives INMD Alternatives IRMD Alternatives TNDM Alternatives KMTS Alternatives EMBC Alternatives SIBN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CATX) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access